Drug Sponsors

Cardinal Health to acquire Johnson & Johnson’s Cordis

Wednesday, March 4, 2015 01:18 PM

Johnson & Johnson has received a binding offer from Cardinal Health, a healthcare services company based in Dublin, Ohio, to acquire its Cordis business for an aggregate value of $1.99 billion, consisting of $1.944 billion of cash proceeds from Cardinal Health plus approximately $46 million of retained net receivables. Cordis is a developer and manufacturer of interventional vascular technology with 2014 net revenues of approximately $780 million.

More... »


Sun Pharma to buy GSK’s Opiates business in Australia

Wednesday, March 4, 2015 01:16 PM

GlaxoSmithKline has reached an agreement with India-based Sun Pharma to sell GSK’s opiates business in Australia, including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria) and its portfolio of opiates products along with inventory, to a subsidiary of Sun Pharma.

More... »


AtheroNova and subsidiary file for Ch. 11 bankruptcy protection

Wednesday, March 4, 2015 01:16 PM

AtheroNova and its subsidiary, AtheroNova Operations, filed voluntary petitions under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court, Central District of California, Santa Ana division on March 2. The company's Chapter 11 cases are expected to be jointly administered.

More... »

Array BioPharma purchases phase III assets from Novartis

Wednesday, March 4, 2015 01:07 PM

Array BioPharma has completed both the binimetinib and encorafenib definitive agreements with Novartis. Along with global ownership of both assets, Array will receive an upfront payment of $85 million from Novartis.

More... »

Teva to sell Sellersville, Pa., facility to G&W Labs

Monday, March 2, 2015 03:08 PM

Jerusalem-based Teva Pharmaceutical Industries will sell its Sellersville, Pa., facility to G&W Laboratories, as part of a plan to streamline operations by reducing excess manufacturing capacity. It is part of Teva’s previously announced cost reduction program.

More... »

GSK, Novartis complete major three-part transaction

Monday, March 2, 2015 03:03 PM

GlaxoSmithKline and Novartis have completed their three-part transaction. As a result, GSK has acquired Novartis' global vaccines business (excluding influenza vaccines) for $5.25 billion and has divested its oncology business to Novartis for $16 billion. In addition, the two have created a new consumer healthcare joint venture in which GSK will have majority control and an equity interest of 63.5%.

More... »

Dicerna Pharmaceuticals moves to Cambridge, Mass., will add 10 jobs

Friday, February 27, 2015 02:30 PM

Dicerna Pharmaceuticals, a developer of RNAi therapeutics, has opened a new 37,000-square-foot office and R&D laboratory in the Alewife area of Cambridge, Mass.

More... »

Biota Pharmaceuticals to acquire Anaconda Pharma

Friday, February 27, 2015 02:29 PM

Biota Pharmaceuticals, based in Alpharetta, Ga., has agreed to acquire Anaconda Pharma, a privately held biotech company based in Paris.

More... »

Sosei acquires Heptares Therapeutics for up to $400M

Wednesday, February 25, 2015 11:36 AM

Sosei Group, a Japanese biopharmaceutical company with operations in Japan and the U.K., has acquired Heptares Therapeutics, a clinical-stage, private U.K.-based biotechnology company focused on creating novel medicines targeting G protein-coupled receptors (GPCRs).

More... »

Turing Pharmaceuticals launched

Wednesday, February 25, 2015 11:32 AM

Turing Pharmaceuticals officially has launched. New York-based Turing will focus on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there currently are limited or no treatment options.

More... »

CenterWatch
CWWeekly

May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

May

Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs